Public-Private PartnershipS

TKI allowance for gelatin nanospheres

Radboud UMC and Rousselot use TKI allowance for gelatin nanospheres

Gelatin nanospheres have recently emerged as promising carriers for (targeted) local delivery of therapeutic biomolecules. However, the production of gelatine nanospheres is still associated with variability among batches and low production volumes. This makes the industrial upscaling and clinical translation complicated. Therefore, the Radboud University Medical Center (department of Biomaterials) and the world-leader in gelatine manufacturing Rousselot NV joined forces in a public-private partnership to optimize the production of gelatine nanospheres by studying the characteristics of gelatin and the resulting nanoparticles.

They used their in kind and in cash contributions to test six types of gelatins to produce gelatin nanospheres. The TKI allowance allowed to broaden the scope of this study by studying a larger number of gelatin types with different chemical properties. More insight in the preparation and characteristics of gelatin nanospheres can provide us with the knowledge needed to develop successful strategies towards (targeted) local delivery of various biomolecules. These future strategies may benefit patients as well as surgeons and companies active in the field of regenerative medicine.